The objective of this study was to investigate the effects of a novel form of biotin (magnesium biotinate) on serum glucose, lipid profile, and hepatic lipid metabolism-related protein levels in rats. Forty-two rats were divided into six groups and fed a standard diet-based egg white powdered diet supplemented with either d-biotin at 0.01, 1, or 100 mg/kg BW or magnesium biotinate at 0.01, 1, or 100 mg/kg BW for 35 days. Neither form of biotin influenced (p > 0.05) serum glucose or insulin concentrations. Serum total cholesterol and triglyceride decreased with biotin from both sources (p < 0.05). Concentrations were lower with magnesium biotinate when comparing the 1 mg/kg dose (p < 0.05). Serum, liver, and brain biotin and liver cyclic guanosine monophosphate (cGMP) concentrations were greater when rats were treated with magnesium biotinate versus d-biotin, particularly when comparing the 1 and 100 mg/kg dose groups (p < 0.05). Both biotin forms decreased the liver SREBP-1c and FAS and increased AMPK-α1, ACC-1, ACC-2, PCC, and MCC levels (p < 0.05). The magnitudes of responses were more emphasized with magnesium biotinate. Magnesium biotinate, compared with a commercial d-biotin, is more effective in reducing serum lipid concentrations and regulating protein levels of lipid metabolism-related biomarkers.

The novel Ni-NTA-functionalized magnetic chitosan microspheres (MCS-NTA-Ni) were prepared via amino functionalization of MCS with epichlorohydrin and ethylenediamine, followed by the introduction of the aldehyde groups and NTA in turn, and nickel (II) ions were chelated in the end. MCS-NTA-Ni contained numerous long-armed NTA-Ni surface groups, ensuring high enzyme loading and providing more space and flexibility to attach enzymes and maintain their activity. This microsphere can have highly selective adsorption of his-tagged recombinant protein. The his-tagged recombinant Microbacterium esterase of E. coli BL21 (DE3)/pET21a-EstSIT01 was first immobilized on MCS-NTA-Ni by affinity fixation, giving high immobilization yield (90.1%) and enzyme loading (120 mg/g). Compared with free esterase, the immobilized esterase was found to exhibit higher pH stability and thermal stability. In addition, the immobilized esterase had excellent reusability for the synthesis of key chiral intermediate of d-biotin and the substrate conversion could still keep 100% after 8 cycles continuously.

A novel, highly soluble biotin salt, magnesium biotinate (MgB), was assessed for general and genetic toxicity using several toxicologic tests. This battery of tests included in vitro bacterial reverse mutation test, in vitro mammalian micronucleus assay, and oral acute, 14-day, and 90-day repeat-dose toxicity in Sprague-Dawley (SD) rats. The results of the in vitro studies indicate that MgB is not mutagenic, clastogenic, or aneugenic. The acute oral toxicity study established an LD50 ≥ 5000 mg MgB/kg. In the 14-day oral toxicity study, doses of MgB up to 2500 mg MgB/kg/day produced no clinical signs or mortality. In the 90-day oral toxicity study, administration of 600 mg MgB/kg/day resulted in no clinical signs and was determined to be the no-observed-adverse-effect-level (NOAEL), which equates to 39 g biotin/day for a 70 kg human. Since MgB is composed of 93% biotin, the 600 mg NOAEL equates to approximately 1.3 million times the current recommended daily allowance of 30 μg biotin/day and 3900 times supplement levels of 10 mg biotin/day. Based on the toxicologic profile and lack of findings in various in vitro and in vivo studies, MgB may be considered safe for long-term human use.

Continuous contact of air pollutants on human skin has produced early ageing and led to roughness, dryness, poor elasticity, increased wrinkling and irregular pigmentation of the skin. The present study was carried out to fabricate an anti-pollution cosmetic-based w/o/w multiple emulsion containing D-biotin, prepared by a one-step formation as protection for the skin against the effects of air pollutants and further used for in vitro and in vivo evaluation. A similar multiple emulsion without D-biotin was also prepared in the same way. Each of the tested multiple emulsions (CB2 and CF2) was applied to the cheeks of 15 human volunteers for a testing period of 90 days. Both emulsions were assessed for skin melanin, erythema, hydration and elasticity values. The droplet sizes of CB2 and CF2 stored in the dark were 10.92 ± 0.23 and 15.4 ± 0.12 μm, respectively. The size distributions of CB2 and CF2 ranged from 4.55 ± 0.1 to 26.056 ± 0.34 μm and from 1.97.16 ± 1.2 to 45.13 ± 2.17 μm, respectively. The rheological parameters showed non-Newtonian, pseudo-plastic and shear thinning behaviour, while pH remained within an acceptable range. No considerable physical changes were observed. The skin irritation testing indicated that CB2 and CF2 were safe after application and did not cause any skin irritation. The skin melanin, erythema, moisture and elasticity values of both the right and left cheeks of the volunteers were measured at baseline visits: 15, 30, 45, 60, 75 and 90 days of time intervals. While CB2 showed insignificant effects, therefore, it was demonstrated that CF2 decreased skin erythema content and increased skin elasticity and hydration significantly but had an insignificant effect on skin melanin content with respect to time. Good sensory attributes were also achieved. Therefore, CF2 is a promising new approach for protection of the skin from the deleterious effects of air pollutants.